{"id":4949,"date":"2025-09-12T09:57:14","date_gmt":"2025-09-12T05:57:14","guid":{"rendered":"https:\/\/medscriptum.org\/?p=4949"},"modified":"2025-09-12T09:57:55","modified_gmt":"2025-09-12T05:57:55","slug":"fda-approves-inlexzo-a-breakthrough-in-bladder-cancer-treatment","status":"publish","type":"post","link":"https:\/\/medscriptum.org\/en\/fda-approves-inlexzo-a-breakthrough-in-bladder-cancer-treatment\/","title":{"rendered":"FDA Approves Inlexzo: A Breakthrough in Bladder Cancer Treatment"},"content":{"rendered":"

On September 9, the U.S. Food and Drug Administration (FDA) approved Inlexzo, an innovative system for an aggressive form of bladder cancer (non-muscle-invasive bladder cancer – NMIBC) that is unresponsive to standard treatment (BCG therapy).<\/p>\n

Bladder cancer is a global problem. One of its common forms, NMIBC, initially involves only the bladder’s mucosal layer. Currently, NMIBC is treated with BCG, an immunotherapy drug made from weakened tuberculosis bacteria. It is administered directly into the bladder to activate the immune system, causing the body to attack cancer cells.<\/p>\n

Although BCG is effective for many patients, some become resistant to it. In these cases, they are left with limited treatment options, often with the only recommended method being radical cystectomy (complete removal of the bladder). This surgery significantly changes a patient’s lifestyle, and the risk of postoperative complications is high.<\/p>\n

How Inlexzo Works:<\/strong><\/p>\n

Inlexzo is the first FDA-approved intravesical drug-releasing system: it releases the anti-cancer drug gemcitabine directly into the bladder over a long period. The system is inserted in an outpatient setting, without general anesthesia, using a special catheter.<\/p>\n

Each treatment cycle lasts three weeks. For the first six months, patients receive eight doses (one dose every three weeks), followed by maintenance doses every three months. Treatment continues for up to 18 months unless the disease progresses or serious side effects appear.<\/p>\n

Clinical Trial Data:<\/strong><\/p>\n

The approval of Inlexzo was based on data from the SunRISe-1 study, which included 83 patients diagnosed with BCG-resistant NMIBC. The study results are reliable: 82% of patients achieved complete remission, and 51% of them maintained remission for one year. To evaluate the effectiveness of the treatment, patients underwent regular cystoscopy, urinalysis, and biopsy.<\/p>\n

Safety and Side Effects:<\/strong><\/p>\n